lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024

IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1 Is it safe? looks it, no serious AES, 6mo follow up Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab Does it work? will have to wait for Phase 2 Somehow bold knowing TCZ did not work in hand OA AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM

• https://twitter.com/i/web/status/1801894324684157080
• https://twitter.com/AurelieRheumo/status/1801894324684157080/photo/1
• https://twitter.com/AurelieRheumo/status/1801894324684157080/photo/1

Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s. This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr

• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1

EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024

Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh

• https://twitter.com/Janetbirdope/status/1801881956491104300/photo/1
• https://twitter.com/Janetbirdope/status/1801881956491104300/photo/1

#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1
• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1

EULAR guidelines for screening for TB in rheumatic disease patients #EULAR2024 https://t.co/jaixl8lGkY

• https://twitter.com/BolekBerqui/status/1801595607275991188/photo/1

POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0

• https://twitter.com/KDAO2011/status/1801539126719594706/photo/1

Maintenance of remission in GPA/MPA. RTX for 48 months sounds good to me. #EULAR2024 https://t.co/5YGwOHhCuX

• https://twitter.com/NoufAhmedAlham2/status/1801589237952782644/photo/1